BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

369.06 5.02 −1.34%
Market cap
$39.0B
P/E
62.6×
Fwd P/E
40.2×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 7 7 8

+8 more TTM periods

ROE
14.66% 12.42% 7.46% 1.81%
ROA
8.47% 7.13% 4.07% 1.02%
ROIC
60.22% 46.03% 36.03% 49.21%
Return on Tangible Assets
9.73% 7.98% 4.75% 1.39%
Average Days of Receivables
62.90 59.66 59.10 63.37
Free Cash Flow per Share
11.92 10.05 8.45 4.76
Free Cash Flow
1,330.19 1,114.61 921.74 524.60
Other line items

Show all line items

Columns are period end dates